Elixirgen Therapeutics Inc
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Elixirgen Therapeutics Inc
Scrip Asks…What Does 2023 Hold For Biopharma? Part 5: Technological Advances
The confluence of data science and molecular biology fuels expectations among biopharma industry leaders for another year of breakthrough innovation in human therapeutics. More than 70 executives and experts reveal what they are most excited about on the technology front.
Deal Watch: AbbVie Partners With Gedeon Richter In Neuropsychiatry
Seeing strong sales with legacy Allergan’s Vraylar, AbbVie teams with Gedeon Richter on novel dopamine receptor modulators. AB Studio, CR Biopharma partner on COVID-19 neutralizing antibody.
Mutation Quirk In NRx’s COVID-19 Vaccine Asset Could Help Fight VOCs
The firm’s live-virus COVID-19 vaccine candidate BriLife is entering a late-stage study following Phase II success, sparking hopes that its spontaneous mutations could parallel those of VOCs.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.